Clinical trial · Interventional
Percutaneous Versus EUS FNAC in Pancreatic Masses
Percutaneous Versus Endoscopic Guided Fine Needle Aspiration Cytology in Diagnosis of Pancreatic Masses
NCT04623749CI-TRIAL-00052268unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We aim to evaluate the role of Ultrasound-guided (USG) fine needle aspiration cytology (FNAC) in diagnosis of pancreatic masses compared to endoscopic ultrasound (EUS) guided fine needle aspiration cytology (FNAC).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Abscess | — | UNRESOLVED | — |
| Pancreatic Cyst | — | UNRESOLVED | — |
| Pancreatic Neoplasm | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EUS | Procedure | — | UNRESOLVED |
| US | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Percutaneous US guided FNAC in pancreatic masses
- interventionNames
- Procedure: US
- type
- ACTIVE_COMPARATOR
- label
- EUS guided FNAC in pancreatic masses
- interventionNames
- Procedure: EUS
Primary outcomes (1)
- measure
- Yield, as defined by the percentage of patients in whom a histologically interpretable specimen will be retrieved by Trans abdominal US-FNAC. diagnostic accuracy
- timeFrame
- intraopeatve
- description
- Percutaneous US guided FNAC technique
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * 50 Patients in different sex \& age groups with pancreatic masses Exclusion Criteria: * Any general contraindications for FNAC or EUS in some cases as Coagulopathy with INR \>1.5 or platelet count \<50,000/mmc, Antithrombotic therapy.
References
Publications (2)
- BACKGROUNDSiegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5. PMID 25559415
- BACKGROUNDEgawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T, Maguchi H, Yanagisawa A, Tanaka M. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas. 2012 Oct;41(7):985-92. doi: 10.1097/MPA.0b013e318258055c. PMID 22750974